↓ Skip to main content

Dove Medical Press

Article Metrics

Intracellular targeted co-delivery of shMDR1 and gefitinib with chitosan nanoparticles for overcoming multidrug resistance

Overview of attention for article published in International Journal of Nanomedicine, November 2015
Altmetric Badge

About this Attention Score

  • Good Attention Score compared to outputs of the same age (67th percentile)
  • Good Attention Score compared to outputs of the same age and source (78th percentile)

Mentioned by

twitter
5 tweeters

Citations

dimensions_citation
21 Dimensions

Readers on

mendeley
24 Mendeley
Title
Intracellular targeted co-delivery of shMDR1 and gefitinib with chitosan nanoparticles for overcoming multidrug resistance
Published in
International Journal of Nanomedicine, November 2015
DOI 10.2147/ijn.s92436
Pubmed ID
Authors

Liang Zhao, Xiwei Yu, Guang Yang, Yijie Shi, Chang Su, Ming Liu, Bo Feng

Abstract

Nowadays, multidrug resistance and side effects of drugs limit the effectiveness of chemotherapies in clinics. P-glycoprotein (P-gp) (MDR1), as a member of the ATP-binding cassette family, acts on transporting drugs into cell plasma across the membrane of cancer cells and leads to the occurrence of multidrug resistance, thus resulting in the failure of chemotherapy in cancer. The main aims of this research were to design a nanodelivery system for accomplishing the effective co-delivery of gene and antitumor drug and overcoming multidrug resistance effect. In this study, shMDR1 and gefitinib-encapsulating chitosan nanoparticles with sustained release, small particle size, and high encapsulation efficiency were prepared. The serum stability, protection from nuclease, and transfection efficiency of gene in vitro were investigated. The effects of co-delivery of shMDR1 and gefitinib in nanoparticles on reversing multidrug resistance were also evaluated by investigating the cytotoxicity, cellular uptake mechanism, and cell apoptosis on established gefitinib-resistant cells. The results demonstrated that chitosan nanoparticles entrapping gefitinib and shMDR1 had the potential to overcome the multidrug resistance and improve cancer treatment efficacy, especially toward resistant cells.

Twitter Demographics

The data shown below were collected from the profiles of 5 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 24 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 24 100%

Demographic breakdown

Readers by professional status Count As %
Student > Ph. D. Student 5 21%
Researcher 5 21%
Student > Bachelor 2 8%
Other 2 8%
Student > Master 2 8%
Other 2 8%
Unknown 6 25%
Readers by discipline Count As %
Pharmacology, Toxicology and Pharmaceutical Science 6 25%
Biochemistry, Genetics and Molecular Biology 3 13%
Medicine and Dentistry 3 13%
Agricultural and Biological Sciences 3 13%
Chemistry 2 8%
Other 2 8%
Unknown 5 21%

Attention Score in Context

This research output has an Altmetric Attention Score of 3. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 11 December 2015.
All research outputs
#2,543,594
of 7,006,881 outputs
Outputs from International Journal of Nanomedicine
#224
of 1,655 outputs
Outputs of similar age
#76,417
of 237,723 outputs
Outputs of similar age from International Journal of Nanomedicine
#25
of 119 outputs
Altmetric has tracked 7,006,881 research outputs across all sources so far. This one has received more attention than most of these and is in the 63rd percentile.
So far Altmetric has tracked 1,655 research outputs from this source. They receive a mean Attention Score of 2.1. This one has done well, scoring higher than 86% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 237,723 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 67% of its contemporaries.
We're also able to compare this research output to 119 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 78% of its contemporaries.